Back
Exelixis, Inc. 10K Form
Buy
67
EXEL
Exelixis, Inc.
Last Price:
$43.63
Seasonality Move:
0.52%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | EXEL/Exelixis, Inc. Quarterly |
| 2023-11-01 | 10Q | EXEL/Exelixis, Inc. Quarterly |
| 2023-08-01 | 10Q | EXEL/Exelixis, Inc. Quarterly |
| 2023-05-09 | 10Q | EXEL/Exelixis, Inc. Quarterly |
| 2022-11-01 | 10Q | EXEL/Exelixis, Inc. Quarterly |
| 2022-08-09 | 10Q | EXEL/Exelixis, Inc. Quarterly |
Receive EXEL News And Ratings
See the #1 stock for the next 7 days that we like better than EXEL
EXEL Financial Statistics
Sales & Book Value
| Annual Sales: | $2.3B |
|---|---|
| Cash Flow: | $332.4M |
| Price / Cash Flow: | 14.04 |
| Annual Sales: | $8.23 |
| Price / Book: | 5.24 |
Profitability
| EPS (TTM): | 2.78380 |
|---|---|
| Net Income (TTM): | $782.6M |
| Gross Margin: | $2.2B |
| Return on Equity: | 36.46% |
| Return on Assets: | 27.54% |
Exelixis, Inc. Earnings Forecast
Key Exelixis, Inc. Financial Ratios
-
The Gross Profit Margin over the past 30 years for EXEL is 96.39%.
-
The Selling, General & Administrative Expenses for EXEL have been equal to 22.36% of Gross Profit Margin.
-
The Research & Development expenses have been 35.56% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of EXEL is 33.73% of Total Revenues.
-
Per Share Earnings over the last 30 years have been positive in 17 years.
Exelixis, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | EXEL |
| CUSIP: | 30161Q |
| Website: | exelixis.com |
Debt
| Debt-to-Equity Ratio: | 0.09 |
|---|---|
| Current Ratio: | 3.56 |
| Quick Ratio: | 3.32 |
Price-to-Earnings
| Trailing P/E Ratio: | 15.71 |
|---|---|
| Forward P/E Ratio: | 10.92 |
EXEL Technical Analysis vs Fundamental Analysis
Buy
67
Exelixis, Inc. (EXEL)
is a Buy
Is Exelixis, Inc. a Buy or a Sell?
-
Exelixis, Inc. stock is rated a BuyThe current Exelixis, Inc. [EXEL] share price is $43.63. The Score for EXEL is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.